Fourth quarter and full year results reflect temporary planned scale back in wholesale production At year-end was back to fully planted with legacy greenhouses and the most overall acreage planted in Glass House history Full year 2026 wholesale cannabis biomass production is forecasted to be approximately 1,000,000 pounds, up approximately 50% from 2025. Year-end 2025 cash and restricted cash balance was $23.4 million, forecasting year-end 2026 cash to exceed $50 million. Conference call to be held today March 24, 2026, at 5:00 p.m. ETLONG BEACH, Calif and TORONTO, March 24, 2026 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in the U.S., today reported financial...

Expands Board as Company Accelerates Growth in Solar Recycling and Critical Metals Recovery VIRGINIA CITY, Nev., March 24, 2026 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock,” “our” and the “Company”), today announced its full year 2025 results, 2025 summary achievements, and our 2026 business outlook. “Last year marked a number of critical achievements that punctuated the turnaround from a junior mining opportunity into a validated, leading metals recovery company positioned for global growth, including final proof of our zero-landfill recycling concept from our demonstration facility, team-building, full permitting, final, first-of-its-kind engineered and tested designs, secured industrial scale facility and storage capacity and fully funded the facility and operations while also receiving direct investment from Marathon...

MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent HighlightsDelivered revenue of $20.9 million in the fourth quarter and $80.3 million for the full year 2025, an 18% and 16% increase, respectively, from the corresponding periods of 2024; Expanded the sales force to 88 quota-carrying representatives as of today under the leadership of commercial management added at midyear; Announcing promotion of Howard Langstein, MD, FACS to Chief Medical Officer, effective March 1, 2026; and Closed on a credit facility for up to $70.0 million from Perceptive Advisors (“Perceptive”). The Perceptive...

POMPANO BEACH, Fla., March 24, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Financial and Business HighlightsGenerated net revenue of $10.1 million for the fourth quarter 2025 and gross margin of 97% Completed the acquisition of the BioTissue Holdings Inc. surgical and wound assets in January 2026, significantly expanding the Company’s product portfolio, commercial footprint, and diversifying end markets into the hospital setting Integrated BioTissue’s experienced national sales force of approximately 20 direct sales representatives and managers, and more...

2025 Full-year results and business update Transgene Continues Progressto Reshape Early-Stage Cancer Treatmentthrough Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028  TG4050, Transgene’s first INTV, demonstrated durable clinical outcomes in resected head and neck squamous cell carcinoma (HNSCC) and potential to prevent cancer relapseRandomization of Phase 2 patients nearly completed -Disease-free survival1 from evaluable patients in the Phase 2 part of the Phase 1/2 study expected 2 years after completion of randomization myvac® platform: new Phase 1 trial in a second indication in operable solid tumors planned to start in 2026 BT-001: Phase 1 results in patients with advanced refractory tumors support further clinical development €111.9 million in cash available as of December 31,...

MIAMI, March 24, 2026 (GLOBE NEWSWIRE) — Standard Premium Finance Holdings, Inc. (OTCQX: SPFX) (“Standard Premium”), a leading specialty finance company, today announces compelling financial and operational results for the 2025 fiscal year, highlighting growth in the Company’s receivables portfolio, net income, strong earnings per share (EPS) and double-digit return-on-equity. “These results demonstrate our continued ability to execute on a proactive growth strategy while maintaining strong financial discipline and the dedication of our team to continue achieving record-breaking profits,” says William Koppelmann, CEO, Standard Premium. “With a solid foundation in place, enhanced liquidity through our new credit facility and a focus on strategic expansion opportunities, we are well-positioned to drive sustained performance and deliver...

MINNETONKA, Minn., March 24, 2026 (GLOBE NEWSWIRE) — Table Trac, Inc. (OTCQX: TBTC), a developer and provider of casino information and management systems that automate and monitor the operations of casinos announced financial results for the year ended December 31, 2025. The 10-K can be found @ http://www.sec.gov 2025 Highlights Record Gross Profit. Record maintenance revenue of $6.15 Million, an approximate 14.4% increase over the prior year. Maintenance revenue accounted for 55.7% of total revenues. Other revenue increased 13.2% as a result of an increase in recurring monthly fees relating to DataTrac and SlotSuite. Table Trac declared and paid quarterly dividends of $0.02 per share in each of the four quarters during 2025. The CasinoTrac system was installed in eight locations during 2025. At the end of 2025, Table Trac had...

Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory biomarkers of cardiovascular risk; Phase 2a proof-of-concept trial planned to initiate in 1H 2026 Indication expansion for BGE-102 into ophthalmology; Phase 1b/2a proof-of-concept trial in diabetic macular edema planned to initiate mid-2026 Completed upsized follow-on public offering of $132.3 million with full exercise of the underwriters’ overallotment option in February 2026 EMERYVILLE, Calif., March 24, 2026 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human...

Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals Compelling real-world performance of VIZZ, combined with broad prescriber uptake and encouraging early refill trends, reinforces confidence in its best-in-class profile and establishment of a durable new category Management to host conference call today, March 24, 2026, at 8:30am EDT SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first...

ATHENS, Greece and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) — Heidmar Maritime Holdings Corp. (the “Company” or “Heidmar”) (NASDAQ: HMR) today reported its results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 HighlightsTotal revenues of $25.1 million, up from $5.3 million in Q4 2024. Net loss from continuing operations attributable to shareholders of $4.0 million or $0.07 loss per share. Cash and cash equivalents of $18.6 million as of December 31, 2025.FOURTH QUARTER 2025 RESULTS COMPARED TO FOURTH QUARTER 2024 Total revenues, earned from commissions, management fees and voyage and time charter hire, were $25.1 million for the three months ended December 31, 2025, compared to $5.3 million for the three months ended December 31, 2024. The increase of $19.8 million is mainly...